A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With or Without Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Gemcitabine (Primary) ; Ubidecarenone (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Berg Pharma
- 10 Jun 2017 Biomarkers information updated
- 07 Dec 2016 Planned number of patients changed from 25 to 50.
- 27 Apr 2016 According to a BERG media release, additional study sites will be added over the next 12 months.